I assume your estimation "that ABBV’s 3-DAA regimen will garner about 100K of the available 260K patients per year in the US and EU, a market share of 38%" refers to a scenario in which both regimens from GILD and ABBV require 12 weeks treatment duration and both contain ribavirin (I think it is pretty sure both regimens have similar SVR rates in this case).
At this point is it safe to assume GILD's Sofosbuvir does not have the risks associated with similar nucs like that from INHX/BMS? Will the safety factor be a concern for some physicians especially if the regimens are longer than 12 weeks? I wonder if there is whether it could lead some physicians to ABBV/ENTA regimen.
Market Data 
Markets 
AI
